The presentations will include an update on the business progress made by the company during the first three quarters of 2024 and look ahead at the expected coming news flow. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain cancer, besides the newly reported phase II data with uTRACE® in brain cancer and the preclinical data using uTREAT® and its impact for the clinical development strategy for the coming year.

The HC Andersen Capital presentation will be webcasted live 13:00 - 13:30 (CET), Friday 15 November 2024 focusing on a Deep Dive in brain cancer.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.

For more information – please click here

The BioStock Life Science Summit 2024 presentation will be a live event in Lund, Sweden, Thursday 21 November 2024.

For more information – please  click here

The Økonomisk Ugebrev Life Science Investor Conference in Copenhagen presentation will be recorded live 17:25 - 17:55 (CET), Wednesday 27 November 2024.

An archive of the presentation can be found on the Økonomisk Ugebrev website as well as Curasight’s website, after the presentation is completed.

For more information – please  click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE^®) and Radioligand Therapy (uTREAT^®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.